ERBB2 and cancer: The images of cancer cells show that only HER2-overexpressing cells (SK-BR3, BT474, MDA-MB361) exposed to NIR-PIT by HER2 Affibody–IR700Dye conjugate displayed morphological evidence of cellular bursting and/or bleb formation, whereas the morphology of HER2 low-expressing cancer cells (MDA-MB231, MDA-MB468) remained unchanged (Figure 7).